{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T14:54:47Z","timestamp":1781880887071,"version":"3.54.5"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2012,2,7]],"date-time":"2012-02-07T00:00:00Z","timestamp":1328572800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int Urogynecol J"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1007\/s00192-011-1641-7","type":"journal-article","created":{"date-parts":[[2012,2,6]],"date-time":"2012-02-06T15:21:40Z","timestamp":1328541700000},"page":"983-991","source":"Crossref","is-referenced-by-count":33,"title":["Solifenacin for overactive bladder: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"23","author":[{"given":"Deyi","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangren","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,2,7]]},"reference":[{"issue":"1","key":"1641_CR1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0090-4295(02)02243-4","volume":"61","author":"P Abrams","year":"2003","unstructured":"Abrams P, Cardozo L, Fall M et al (2003) The standardisation of terminology in lower urinary tract function: report from the standardisation subcommittee of the International Continence Society. Urology 61(1):37\u201349","journal-title":"Urology"},{"issue":"9","key":"1641_CR2","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1046\/j.1464-410x.2001.02228.x","volume":"87","author":"I Milsom","year":"2001","unstructured":"Milsom I, Abrams P, Cardozo L et al (2001) How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 87(9):760\u2013766","journal-title":"BJU Int"},{"key":"1641_CR3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eursup.2006.09.001","volume":"6","author":"CR Chapple","year":"2007","unstructured":"Chapple CR (2007) Advancing the management of overactive bladder: new data, new directions. Eur Urol Suppl 6:1\u20133","journal-title":"Eur Urol Suppl"},{"key":"1641_CR4","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.eururo.2006.04.018","volume":"50","author":"P Reeves","year":"2006","unstructured":"Reeves P, Irwin D, Kelleher C et al (2006) The current and future burden and cost of overactive bladder in five European countries. Eur Urol 50:1050\u20131057","journal-title":"Eur Urol"},{"key":"1641_CR5","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.eursup.2007.01.002","volume":"6","author":"C Hampel","year":"2007","unstructured":"Hampel C (2007) Long-term management of overactive bladder with antimuscarinic agents. Eur Urol Suppl 6:432\u2013437","journal-title":"Eur Urol Suppl"},{"key":"1641_CR6","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.eururo.2005.05.015","volume":"48","author":"CR Chapple","year":"2005","unstructured":"Chapple CR, Martinez-Garcia R, Selvaggi L et al (2005) A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 48:464\u2013470","journal-title":"Eur Urol"},{"issue":"11","key":"1641_CR7","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1111\/j.1742-1241.2008.01898.x","volume":"62","author":"MS Choo","year":"2008","unstructured":"Choo MS, Lee JB, Kim YH et al (2008) Efficacy and safety of solifenacin succinate in Korean patients with overactive bladder: a randomized, prospective, double-blind, multicentre study. Int J Clin Pract 62(11):1675\u20131683","journal-title":"Int J Clin Pract"},{"key":"1641_CR8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1\u201312","journal-title":"Control Clin Trials"},{"issue":"9","key":"1641_CR9","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1111\/j.1464-410X.2008.07939.x","volume":"102","author":"L Cardozo","year":"2008","unstructured":"Cardozo L, Hessd\u00f6rfer E, Milani R, SUNRISE Study Group et al (2008) Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial. BJU Int 102(9):1120\u20131127","journal-title":"BJU Int"},{"issue":"1","key":"1641_CR10","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.urology.2008.08.485","volume":"73","author":"MM Karram","year":"2009","unstructured":"Karram MM, Toglia MR, Serels SR et al (2009) Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial. Urology 73(1):14\u201318","journal-title":"Urology"},{"issue":"5","key":"1641_CR11","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3810\/pgm.2009.09.2062","volume":"121","author":"MR Toglia","year":"2009","unstructured":"Toglia MR, Serels SR, Laram\u00e9e C et al (2009) Solifenacin for overactive bladder: patient-reported outcomes from a large placebo-controlled trial. Postgrad Med 121(5):151\u2013158","journal-title":"Postgrad Med"},{"issue":"7","key":"1641_CR12","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s00192-010-1120-6","volume":"21","author":"MR Toglia","year":"2010","unstructured":"Toglia MR, Ostergard DR, Appell RA et al (2010) Solifenacin for overactive bladder: secondary analysis of data from VENUS based on baseline continence status. Int Urogynecol J Pelvic Floor Dysfunct 21(7):847\u2013854","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"issue":"10","key":"1641_CR13","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1185\/03007995.2010.509582","volume":"26","author":"SR Serels","year":"2010","unstructured":"Serels SR, Toglia MR, Forero-Schwanhaeuser S et al (2010) Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms. Curr Med Res Opin 26(10):2277\u20132285","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"1641_CR14","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.eururo.2007.05.027","volume":"52","author":"CR Chapple","year":"2007","unstructured":"Chapple CR, Fianu-Jonsson A, Indig M et al (2007) STAR study group. Treatment outcomes in the STAR study: a subanalysis of solifenacin 5\u00a0mg and tolterodine ER 4\u00a0mg. Eur Urol 52(4):1195\u20131203","journal-title":"Eur Urol"},{"issue":"3","key":"1641_CR15","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1464-410X.2004.04606.x","volume":"93","author":"CR Chapple","year":"2004","unstructured":"Chapple CR, Rechberger T, Al-Shukri S et al (2004) YM-905 Study Group. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 93(3):303\u2013310","journal-title":"BJU Int"},{"issue":"10","key":"1641_CR16","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S0929-6646(10)60114-3","volume":"109","author":"CH Ho","year":"2010","unstructured":"Ho CH, Chang TC, Lin HH et al (2010) Solifenacin and tolterodine are equally effective in the treatment of overactive bladder symptoms. J Formos Med Assoc 109(10):702\u2013708","journal-title":"J Formos Med Assoc"},{"issue":"1","key":"1641_CR17","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1464-410X.2004.04561.x","volume":"93","author":"CR Chapple","year":"2004","unstructured":"Chapple CR, Ara\u00f1o P, Bosch JL et al (2004) Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. BJU Int 93(1):71\u201377","journal-title":"BJU Int"},{"issue":"12","key":"1641_CR18","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1111\/j.1742-1241.2009.02209.x","volume":"63","author":"MD Vardy","year":"2009","unstructured":"Vardy MD, Mitcheson HD, Samuels TA et al (2009) Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRANT\u2014a double-blind, placebo-controlled trial. Int J Clin Pract 63(12):1702\u20131714","journal-title":"Int J Clin Pract"},{"issue":"5 Pt 1","key":"1641_CR19","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1097\/01.ju.0000140729.07840.16","volume":"172","author":"L Cardozo","year":"2004","unstructured":"Cardozo L, Lisec M, Millard R et al (2004) Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 172(5 Pt 1):1919\u20131924","journal-title":"J Urol"},{"issue":"suppl 1","key":"1641_CR20","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1464-410X.2005.05651.x","volume":"96","author":"MC Michel","year":"2005","unstructured":"Michel MC, de la Rosette JJ (2005) Role of muscarinic receptor antagonists in urgency and nocturia. BJU Int 96(suppl 1):37\u201342","journal-title":"BJU Int"},{"key":"1641_CR21","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1097\/01.ju.0000103540.71683.e5","volume":"171","author":"RJ Landis","year":"2004","unstructured":"Landis RJ, Kaplan S, Swift S et al (2004) Efficacy of antimuscarinic therapy for overactive bladder with varying degree of incontinence severity. J Urol 171:752\u2013756","journal-title":"J Urol"},{"key":"1641_CR22","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.amjmed.2005.12.013","volume":"119","author":"DR Staskin","year":"2006","unstructured":"Staskin DR, MacDiarmid SA (2006) Pharmacologic management of overactive bladder: practical options for the primary care physician. Am J Med 119:24\u201328","journal-title":"Am J Med"},{"issue":"4","key":"1641_CR23","first-page":"CD003193","volume":"18","author":"AA Alhasso","year":"2006","unstructured":"Alhasso AA, McKinlay J, Patrick K et al (2006) Anticholinergic drugs versus non-drug active therapies for overactive bladder syndrome in adults. Cochrane Database Syst Rev 18(4):CD003193","journal-title":"Cochrane Database Syst Rev"},{"key":"1641_CR24","first-page":"2061","volume":"74","author":"BJ Epstein","year":"2006","unstructured":"Epstein BJ, Gums JG, Molina E (2006) Newer agents for the management of overactive bladder. Am Fam Physician 74:2061\u20132068","journal-title":"Am Fam Physician"},{"key":"1641_CR25","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.eururo.2008.06.047","volume":"54","author":"CR Chapple","year":"2008","unstructured":"Chapple CR, Khullar V, Gabriel Z et al (2008) The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 54:543\u2013562","journal-title":"Eur Urol"},{"key":"1641_CR26","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S0031-6997(25)06957-1","volume":"48","author":"RM Eglen","year":"1996","unstructured":"Eglen RM, Hedge SS, Watson N (1996) Muscarinic receptor subtypes and smooth function. Pharmacol Rev 48:531\u2013565","journal-title":"Pharmacol Rev"},{"key":"1641_CR27","unstructured":"Haab F, Van Kerrebroeck P, Huang M, et al (2004) Solifenacin associated with high persistence on therapy in long-term overactive bladder extension study Third International consultation on Incontinence; June 26\u201328 (Monte Carlo): Monaco"},{"issue":"Suppl 5A","key":"1641_CR28","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0090-4295(99)00492-6","volume":"55","author":"CR Chapple","year":"2000","unstructured":"Chapple CR (2000) Muscarinic receptor antagonists in the treatment of overactive bladder. Urology 55(Suppl 5A):33\u201346","journal-title":"Urology"},{"key":"1641_CR29","first-page":"191","volume":"27","author":"DA Ginsberg","year":"2007","unstructured":"Ginsberg DA, Phillips SE, Wallace J et al (2007) Evaluating and managing constipation in the elderly. Urol Nurs 27:191\u2013200","journal-title":"Urol Nurs"},{"issue":"Suppl 3","key":"1641_CR30","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.3949\/ccjm.74.Suppl_3.S21","volume":"74","author":"MT Rosenberg","year":"2007","unstructured":"Rosenberg MT, Newman DK, Tallman CT et al (2007) Overactive bladder: recognition requires vigilance for symptoms. Cleve Clin J Med 74(Suppl 3):S21\u2013S29","journal-title":"Cleve Clin J Med"},{"key":"1641_CR31","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1464-410X.2007.07205.x","volume":"100","author":"P Abrams","year":"2007","unstructured":"Abrams P, Andersson KE (2007) Muscarinic receptor antagonists for overactive bladder. BJU Int 100:987\u20131006","journal-title":"BJU Int"}],"container-title":["International Urogynecology Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00192-011-1641-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00192-011-1641-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00192-011-1641-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T23:14:04Z","timestamp":1742426044000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00192-011-1641-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,7]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["1641"],"URL":"https:\/\/doi.org\/10.1007\/s00192-011-1641-7","relation":{},"ISSN":["0937-3462","1433-3023"],"issn-type":[{"value":"0937-3462","type":"print"},{"value":"1433-3023","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,7]]}}}